Natco Pharma Ltd.
Fundamentals
- Market cap
- ₹18,196 cr
- P/E
- 12.83×
- ROE
- 24.79%
- Debt / equity
- 0.04
- Div yield
- 0.59%
- 52-week range
- 789.00 — 1226.80
The timeline — 3 notes on Natco Pharma Ltd.
May 2026
- 29 May 26 · 7:14 PM IST Brief Brief · Concalls · Mid cap
Natco's trough is here. The growth math starts next year.
FY27 profit guidance of ₹700-750 cr quantifies the Revlimid hit. From FY28, management targets 15-25% annual earnings growth and is ready to spend ₹2,400 cr on deals.
- 29 May 26 · 4:18 PM IST Brief Brief · Earnings · Mid cap
Natco Pharma files audited results for FY26
The company confirms previously disclosed annual figures of ₹4,375.9 crore in revenue and ₹1,418.5 crore in net profit.
- 29 May 26 · 4:09 PM IST Brief Brief · Earnings · Mid cap
Natco Pharma profit drops 25% as annual revenue slips
The drugmaker reported annual revenue of ₹4,375.9 crore, with fourth-quarter sales falling 36% compared to the same period last year.